ATAI Life Sciences N.V. Stock News

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO Dr Srinivas Rao talked with Proactive about the company's upcoming clinical milestones and strategic focus in 2025. Rao outlined four major clinical readouts across atai's pipeline of short-duration psychedelics, including updates on VLS-01, BPL-003, RL-007 and EMP-01.

After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have high expectations.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is entering a pivotal period with data from several key trials expected in 2025 and 2026, analysts at Jefferies have highlighted following the company's fourth quarter update.  “We see a catalyst-rich period with five-plus Phase 2/3 central nervous systems/neuro readouts in 2025 to 2026,” the analysts wrote in a note to clients.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said it saw significant progress in 2024 with key advancements in its clinical trials as it strengthened its financial position. The company successfully dosed its first patient in the Phase 2 Elumina trial for VLS-01, a buccal film formulation of DMT designed to treat treatment-resistant depression.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that the first patient has been dosed in its Phase 2 Elumina trial of VLS-01, the company's oral transmucosal film formulation of DMT applied to the buccal surface, in participants with treatment-resistant depression. Topline results are expected from the first treatment phase of the trial in the first quarter of 2026.

- Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability of VLS-01 (buccal film DMT) in people suffering from treatment-resistant depression

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that patient enrollment has been completed in Beckley Psytech's Phase 2b trial evaluating BPL-003 in treatment-resistant depression (TRD), with topline results expected by mid-2025. The trial is assessing the efficacy and safety of a single dose of BPL-003, an intranasal formulation of mebufotenin benzoate developed by Beckley Psytech, in whic...

Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds. Standing on the shoulders of Johnson & Johnson's Spravato.